{"id":"levofloxacin-ceftriaxone","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tendinitis/tendon rupture (fluoroquinolone-associated)"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Hypersensitivity reactions (cephalosporin-associated)"}]},"_chembl":{"chemblId":"CHEMBL33","moleculeType":"Small molecule","molecularWeight":"361.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levofloxacin is a fluoroquinolone that disrupts bacterial DNA replication by inhibiting topoisomerases, while ceftriaxone is a beta-lactam antibiotic that binds penicillin-binding proteins and prevents peptidoglycan cross-linking in the bacterial cell wall. Together, they provide synergistic bactericidal activity against a wide range of aerobic and some anaerobic pathogens, reducing the likelihood of resistance development.","oneSentence":"This combination uses a fluoroquinolone antibiotic to inhibit bacterial DNA gyrase and topoisomerase IV, while a third-generation cephalosporin inhibits bacterial cell wall synthesis, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:44.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Complicated urinary tract infections"},{"name":"Intra-abdominal infections"},{"name":"Bacterial infections requiring broad-spectrum coverage"}]},"trialDetails":[{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":"Community Acquired Pneumonia in Children","enrollment":236},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT07229755","phase":"PHASE2, PHASE3","title":"Comparison Between Effect of Empirical Antibiotic Prophylaxis Versus Enhanced Prophylactic Measures on Rate of Urinary Tract Infection After Flexible Ureteroscopy in Children With Pyuria","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-07-01","conditions":"Urinary Tract Infection (Diagnosis)","enrollment":140},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02424461","phase":"PHASE3","title":"Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-01-25","conditions":"Acute Male Urinary Tract Infection","enrollment":274},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT03641690","phase":"","title":"Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2013-09-01","conditions":"H1N1 Influenza","enrollment":97},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT03087656","phase":"PHASE4","title":"Antibiotics to Decrease Post ERCP Cholangitis","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2017-03-29","conditions":"Cholangitis","enrollment":200},{"nctId":"NCT02567825","phase":"NA","title":"Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media","status":"COMPLETED","sponsor":"Alejandro Hoberman","startDate":"2015-11","conditions":"Acute Otitis Media","enrollment":250},{"nctId":"NCT04879030","phase":"PHASE2, PHASE3","title":"Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2020-01-01","conditions":"COPD Exacerbation Acute","enrollment":170},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT00035347","phase":"PHASE4","title":"Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-01","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":219},{"nctId":"NCT02031588","phase":"","title":"Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-12","conditions":"Bacterial Infections","enrollment":77},{"nctId":"NCT00431678","phase":"PHASE3","title":"Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-01","conditions":"Pneumonia","enrollment":738},{"nctId":"NCT01757236","phase":"PHASE2","title":"Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-10","conditions":"Hip Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT02123628","phase":"PHASE4","title":"Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2007-06","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT01660204","phase":"NA","title":"Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2011-02","conditions":"Community-acquired Pneumonia","enrollment":2283},{"nctId":"NCT00257049","phase":"PHASE2, PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1984-01","conditions":"Pneumonia","enrollment":604},{"nctId":"NCT00034736","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-08","conditions":"Pneumonia","enrollment":691},{"nctId":"NCT00429975","phase":"PHASE4","title":"Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia","status":"TERMINATED","sponsor":"Hospital Mutua de Terrassa","startDate":"2004-08","conditions":"Pneumonia, Pneumococcal","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levofloxacin + Ceftriaxone","genericName":"Levofloxacin + Ceftriaxone","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a fluoroquinolone antibiotic to inhibit bacterial DNA gyrase and topoisomerase IV, while a third-generation cephalosporin inhibits bacterial cell wall synthesis, providing broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Community-acquired pneumonia, Complicated urinary tract infections, Intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}